Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005–2015

Abstract

Background Since in low incidence TB countries population migration and complex treatment of drug-resistant tuberculosis (DR-TB) patients are major issues, we aimed to analyse patient risk factors associated with the incidence of poor outcome of TB treatment among DR-TB patients in the Netherlands. Methods This retrospective cohort study included adult patients with confirmed DR-TB treated from 2005 to 2015. We obtained data from a nationwide exhaustive registry of tuberculosis patients in the Netherlands. Predictors for unsuccessful TB treatment (defaulted and failed treatment) and TB-associated mortality were analysed using multivariate logistic regression. Results Among 10,303 registered TB patients, 545 patients with DR-TB were analysed. Six types of DR-TB were identified from the included patients, i.e. isoniazid mono- or poly-resistance (68%); rifampicin mono- or poly-resistance (3.1%); pyrazinamide mono-resistance (8.3%); ethambutol mono-resistance (0.1%); multidrug-resistance (18.9%); and extensively drug-resistance (0.7%). The majority of patients were foreign-born (86%) and newly diagnosed TB (89%) patients. The cumulative incidence of unsuccessful treatment and mortality were 5 and 1%, respectively. Among all DR-TB cases, patients with Multi Drug-Resistant Tuberculosis (MDR-TB) (OR 4.43; 95%CI 1.70–11.60) were more likely to have unsuccessful treatment, while miliary and central nervous system TB (OR 15.60; 95%CI 2.18–111.52) may also be predictors for TB mortality. Additionally, patients with substance abuse and homelessness tend to have unsuccessful treatment. Conclusions In recent years, we identified a low incidence of DR-TB as well as the poor outcome of DR-TB treatment. The majority of cases were primary drug-resistant and foreign-born. To further improve treatment outcome, special attention should be given to the high-risk DR-TB patients. Electronic supplementary material The online version of this article (10.1186/s13756-019-0561-z) contains supplementary material, which is available to authorized users.

Who is doing worse? Retrospective cross-sectional study of TB key population treatment outcomes in Kyrgyzstan (2015-2017)

“…Several studies showed results similar to ours, pointing out that being homeless or a PWUD can lead to worse TB treatment outcomes than being a migrant [20]. A study from the Netherlands showed that being a migrant was not included in a multivariate model of risk factors for unsuccessful treatment outcomes, while being homeless or a PWUD were shown to increase the risk by 9.1 and 6.7 times, respectively [21]. In Italy, the treatment success rate was found to be the same for the migrants and the general population [22] , while in Switzerland, the risk of potentially unsatisfactory outcome was associated with being an asylum seeker (OR = 1.9), while there was almost no association with being a migrant (OR = 1.1) [23].…”

A retrospective study on Tuberculous Lymphadenitis; A retrospective finding from multicenters referal hospitals

“…This study reported that younger age group between 16-35 years were found to have unsuccessful treatment outcomes which may be due to no follow up or any confounding factors. In Yemen a study was performed among general population and it shows homelessness, male gender and age ≥ 25 years were the risk factors reported for poor treatment outcomes [25]. Furthermore, in Netherlands recently a study showed predictors for mortality were aged 74-84 years (OR, 5.58; 95% CI 3.10-10.03) or ≥ 85 years which is contradictory to current study results as these were not specific to lymphadenitis Tuberculosis [26].…”

Characteristics of pulmonary multidrug-resistant tuberculosis patients in Tigray Region, Ethiopia: A cross-sectional study

“…The treatment success rate observed in the Tigray Region was also lower than other regions such as the Afar Region in Ethiopia, which recorded a treatment success rate of 89% [ 13 ]. The major factor leading to a poor treatment success rate is treatment failure, which is mostly caused by drug-resistant (DR-TB) strains [ 13 , 14 ].…”